


Inaperisone

Chemical Properties

| | |
|-------------------|------------------------------------------------------------------------------------------------------------------------|
| CAS No. : | 99323-21-4 |
| Formula: | C ₁₆ H ₂₃ NO |
| Molecular Weight: | 245.36 |
| Storage: | Pure form: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description | Inaperisone is a novel centrally acting muscle relaxant that inhibits the voiding reflex. Inaperisone may inhibit the voiding reflex by acting indirectly on GABAB receptors in the brainstem. |
| Targets(IC50) | Others,GABA Receptor |
| In vivo | Inaperisone (4 mg/kg i.v. ; normal and decerebrated rats) abolished rhythmic bladder contractions observed contractions.[1] The doses of intracerebroventricularly (i.c.v.) and intrathecally injected inaperisone which abolished the rhythmic bladder contractions were 10 and 100 micrograms, respectively.[1] |

Solubility Information

| | |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Solubility | DMSO: 50 mg/mL (203.78 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.15 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 4.0756 mL | 20.3782 mL | 40.7564 mL |
| 5 mM | 0.8151 mL | 4.0756 mL | 8.1513 mL |
| 10 mM | 0.4076 mL | 2.0378 mL | 4.0756 mL |
| 50 mM | 0.0815 mL | 0.4076 mL | 0.8151 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Morikawa K, et al. Inhibitory effect of inaperisone hydrochloride (inaperisone), a new centrally acting muscle relaxant, on the micturition reflex. *Eur J Pharmacol.* 1992 ; 213(3):409-415.

Sugaya K, et al. Identification of effective region of the pons in response to inaperisone which facilitates urine storage. *Hinyokika Kyo.* 1991 ; 37(12):1639-1644.

Doi T, et al. Effects of TAK-637, a tachykinin receptor antagonist, on lower urinary tract function in the guinea pig. *Eur J Pharmacol.* 1999 ; 383(3):297-303.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481